Open-label, Crossover, Food Effect Study to Evaluate CT-044 in Healthy Human Volunteers

Open-label, Crossover, Food Effect Study to Evaluate the Single Dose Pharmacokinetics of CT-044, a Reactive Species Decomposition Accelerant, in Healthy Human Volunteers

This open-label study will be conducted to assess the bioavailability and PK of oral single doses of CT-044 following administration with and without food and to evaluate the safety and tolerability of CT-044 when given with and without food.

Study Overview

• Status: Completed
• Conditions: Surgery; Pain, Acute; Acute Pain; Neuropathy
• Intervention / Treatment: Drug: CT-044

Detailed Description

The food effect study will be an open-label, 2-sequence, balanced crossover design in 12 subjects previously untreated with CT-044.

Eligible subjects will be admitted to the Clinical Trial Unit on the day prior to dosing and remain in house until Day 3. Each subject will receive CT-044 single oral dose once under fed conditions (i.e., a high fat meal per FDA recommendations) and once in the fasted state.

9 Subjects will return to the Clinical Trial Unit on an outpatient basis for follow-up. Subjects will return to the Clinical Trial Unit to be treated by the second sequence after a washout period of at least 7 days, but no more than 14 days. All procedures will be repeated for the second treatment sequence. When possible, the procedures conducted at the 144-hour follow-up visit for the first sequence may serve as baseline for the second sequence of the crossover.

• Study Type: Interventional
• Enrollment (Actual): 10
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • Pasadena, California, United States, 91105
      • Lotus Clinical Resarch,LLC

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Men and women aged 18 through 55 years, inclusive.
• Body mass index within the range 18.5 to 32.0 kg/m2 (inclusive).
• Healthy subjects as determined by medical history, physical examination including neurological examination, vital signs, electrocardiogram (ECG), and clinical laboratory tests.
• Negative tests for hepatitis B surface antigen, hepatitis C virus antibodies and human immunodeficiency virus (HIV-1 or HIV-2) antibody, and syphilis at screening.
• Nonsmokers or ex-smokers and agrees not to use nicotine containing products from screening through 48 hours after final discharge from the Clinical Trial Unit.
• Negative screen for alcohol and drugs of abuse at screening and admission.
• Women must not be of childbearing potential by reason of surgery or at least 1 year postmenopausal (i.e., 12 months without menstrual period), or menopause confirmed with an estradiol level of <30 pg/mL and follicle-stimulating hormone level of >40 IU/L at screening.
• Men must be infertile, or truly abstinent of heterosexual intercourse, or heterosexual partner is not of childbearing potential, or must agree to use an effective method of contraception throughout the study and for 28 days after last dose of study drug. Men must agree to not provide sperm donation during that same period.
• Able and willing to be available for the duration of the study.
• Willing and able to give written informed consent to participate.
• Able to understand and comply with protocol instructions.
• Agree not to receive any vaccination within 21 days prior to admission and through Day 7 after final discharge from the Clinical Trial Unit.
• Agrees not to use nonprescription drugs, including vitamins, antacids, and herbal and dietary supplements within 14 days or 5 drug elimination half-lives, whichever is longer.

Exclusion Criteria:

- Subjects with significant previous or ongoing disease or disorder, including for example: cardiovascular diseases; hypertension; cancer or neoplasia; diabetes; hepatic, endocrine, metabolic, respiratory, renal, gastrointestinal (except appendectomy), hematological or Axis I or II psychiatric disorders.

• Clinical laboratory test results outside the normal range at screening that are considered clinically significant by the Investigator.
• Clinically significant, in the opinion of the Investigator, infection or inflammation at time of screening or admission.
• Acute gastrointestinal symptoms at time of screening or admission or a clinical diagnosis of irritable bowel syndrome (IBS) per ROME IV criteria.
• Average QTcF interval recorded on screening and pre-dose ECG must be not more than 450 msec.
• Any current or previous illicit use of Class A drugs such as opiates, cocaine, ecstasy, lysergic acid diethylamide (LSD), and amphetamines (Class B).
• An alcoholic intake greater than 14 units per week or unwillingness to stop alcohol consumption for the duration of the study.
• Use of any investigational medication within 3 months prior to the start of this study or scheduled to receive an investigational drug during the course of this study, or for 30 days or five half-lives, whichever is longer, following the last dose of study medication.
• History of severe allergies or multiple adverse drug reactions, including penicillin and cephalosporins.
• Any condition which compromises their ability to give informed consent or to communicate with the Investigator as required for the completion of this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: CT-044 600 mg; The dose to be utilized for the evaluation of food effect will be CT-044 600 mg single dose.	Drug: CT-044; CT-044 HCl is a reactive species decomposition accelerant

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Comparison of the maximum drug concentration	Following administration with and without food (Cmax) of oral single dose of CT-044	7 days
Comparison of the Time of maximum drug concentration (tmax)	Following a single oral dose of CT-044 following administration with and without food	7 days
Comparison of the Area under the drug concentration Time curve from time 0 extrapolated to infinity (AUC0-∞)	Following a single oral dose of CT-044 following administration with and without food	7 days
Comparison of the Area under the drug concentration Time curve from time 0 to the time of the last quantifiable concentration (AUC0-last)	Following a single oral dose of CT-044 following administration with and without food	7 days
Comparison of the Apparent oral clearance (CL/F)	Following a single oral dose of CT-044 following administration with and without food	7 days
Comparison of the Apparent volume distribution (Vz/F)	Following a single oral dose of CT-044 following administration with and without food	7 days
Comparison of the Terminal half-life (t1/2)	Following a single oral dose of CT-044 following administration with and without food	7 days
Comparison of the Terminal rate constant (λz)	Following a single oral dose of CT-044 following administration with and without food	7 days
Comparison of the Relative bioavailability	Following a single oral dose of CT-044 after administration of a high-fat meal (F)	7 days
Peak Plasma Concentration (Cmax)	Linear mixed model appropriate for a 2-period cross-over design with fixed terms for sequence, period and food condition will be used to investigate the food interaction on the Peak Plasma Concentration (Cmax)	7 days
Plasma concentration versus time curve (AUC)	Linear mixed model appropriate for a 2-period cross-over design with fixed terms for sequence, period and food condition will be used to investigate the food interaction Area under the plasma concentration versus time curve (AUC)	7 days

Collaborators and Investigators

• Sponsor: Lotus Clinical Research, LLC
• Collaborators: CerSci Therapeutics

Publications and helpful links

General Publications

• Squillace S, Salvemini D. Nitroxidative stress in pain and opioid-induced adverse effects: therapeutic opportunities. Pain. 2022 Feb 1;163(2):205-213. doi: 10.1097/j.pain.0000000000002347. No abstract available.

Study record dates

Study Major Dates

• Study Start (ACTUAL): February 18, 2020
• Primary Completion (ACTUAL): March 16, 2020
• Study Completion (ACTUAL): March 16, 2020

Study Registration Dates

• First Submitted: December 3, 2019
• First Submitted That Met QC Criteria: January 30, 2020
• First Posted (ACTUAL): February 5, 2020

Study Record Updates

• Last Update Posted (ACTUAL): June 12, 2020
• Last Update Submitted That Met QC Criteria: June 11, 2020
• Last Verified: June 1, 2020

More Information

Terms related to this study

• Keywords: Safety; Pharmacokinetics; PK; Tolerability; Food Effect; Single Dose; CT-044 HCl
• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Acute Pain
• Other Study ID Numbers: CT044-003

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No